Ursula A. Matulonis, MD, on Various Advancements in Gynecologic Cancers Presented at SGO 2021

March 23, 2021
Ursula A. Matulonis, MD

CancerNetwork® discussed updates in the treatment of gynecologic cancers with Ursula A. Matulonis, MD.

CancerNetwork® sat down with Ursula A. Matulonis, MD, who is chief of the Division of Gynecologic Oncology at the Dana-Farber Cancer Institute as well as a professor of medicine at Harvard Medical School, to discuss data presented at the virtual Society of Gynecologic Oncology (SGO) 2021 Annual Meeting on Women’s Cancer and what abstracts she believes have the greatest potential to shift the treatment paradigm in various gynecologic cancers.

She first pointed to data presented from the KEYNOTE-775 trial (NCT03517449), which showed that pembrolizumab (Keytruda) plus lenvatinib (Lenvima) administered to patients with advanced, metastatic, or recurrent endometrial cancer who had previously received 1 prior platinum-based regimen in any setting resulted in improved progression-free survival (PFS) and overall survival (OS) versus those treated with physician’s choice therapy.

She also mentioned updated results of the phase 2 KEYNOTE-158 study (NCT02628067) of pembrolizumab in the treatment of advanced cervical cancer as well as a study examining tumor infiltrating lymphocytes, or TILS (LN-145), in recurrent cervical cancer.1,2

Transcription:

They are a lot of practice-changing abstracts being presented. Obviously, KEYNOTE-775 was presented showing improvement of pembrolizumab with lenvatinib in women with recurrent endometrial cancer, mostly in mismatch-repair proficient tumors. That’s practice changing. I gave up a distillation of that on Friday and it really opens up the next steps for improvement in outcomes for women with endometrial cancer and puts a spotlight on this cancer that it’s never [had] before. That’s really exciting for me to see.

There was also data on pembrolizumab presented yesterday, [updating] results in recurrent cervix cancer. Then [the was an abstract about] tumor infiltrating lymphocytes also presented for cervical cancer, so a lot of really great abstracts are being presented.

References

1. Cheol Chung H, Delord JP, Perets R, et al. Pembrolizumab treatment of advanced cervical cancer: updated results from the phase 2 KEYNOTE-158 study. Presented at: Society of Gynecologic Oncology (SGO) 2021 Annual Meeting on Women’s Cancer. March 22-25, 2021.

2. Jazaeri AA, Zsiros E, Amaria RN, et al. Safety and efficacy of adoptive cell transfer using autologous tumor infiltrating lymphocytes (LN-145) for treatment of recurrent, metastatic, or persistent cervical carcinoma. Presented at: Society of Gynecologic Oncology (SGO) 2021 Annual Meeting on Women’s Cancer. March 22-25, 2021.